Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | CDC25A | P30304 | 1/20 | 0.54 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.52 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6268031 | 1.00 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL2370673 | 1.00 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL15566127 | 1.00 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL5251441 | 1.00 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL8960305 | 1.00 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL9073605 | 1.00 | LMNA (0.54) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL6384775 | 0.94 | MEN1 (0.53) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL7515687 | 0.94 | PLA2G1B (0.49) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL9005240 | 0.92 | LMNA (0.46) | LMNAESR1ADORA3CDC25AAGTR1 | |
| SCHEMBL18554720 | 0.92 | LMNA (0.46) | LMNAESR1ADORA3CDC25AAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108585-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | SDG, INC. | 2024-04-04 | — | — | US | claimed |
| US-20240041786-A1 | AMINO ALCOHOL IONIZABLE LIPIDS | NEW JERSEY INSTITUTE OF TECHNOLOGY (US) | 2024-02-08 | — | — | US | claimed |
| US-20240009281-A1 | MRNA THERAPY FOR POMPE DISEASE | Translate Bio, Inc | 2024-01-11 | — | — | US | claimed |
| US-20230310571-A1 | HUMAN METAPNEUMOVIRUS VACCINES | SANOFI PASTEUR INC (US) | 2023-10-05 | — | — | US | claimed |
| US-20230277457-A1 | METHODS OF PREPARING LIPID NANOPARTICLES | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-07 | — | — | US | claimed |
| US-11666534-B2 | Methods of administering lipid formulations with viral immunogens | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-06-06 | — | — | US | claimed |
| US-11638694-B2 | Vaccine for eliciting immune response comprising lipid formulations and RNA encoding multiple immunogens | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-05-02 | — | — | US | claimed |
| CN-115032286-A | Application of composition in preparation of medicine for diagnosing infantile hemangioma and/or monitoring progression and prognosis of infantile hemangioma, kit and medicine | 江成鸿 | 2022-09-09 | — | — | CN | claimed |
| US-20200375913-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | SDG, INC. | 2020-12-03 | — | — | US | claimed |
| US-10369122-B2 | Benzene-1,3,5-tricarboxamide derivatives and uses thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2019-08-06 | — | — | US | claimed |
| US-20190054021-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG, INC. | 2019-02-21 | — | — | US | claimed |
| WO-2018160865-A1 | ACTIVE TARGETING OF CELLS BY MONOSIZED PROTOCELLS | BRINKER CHARLES JEFFREY (US) | 2018-09-07 | — | — | WO | claimed |
| EP-3302436-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | The General Hospital Corporation (US) | 2018-04-11 | — | — | EP | claimed |
| US-20180008591-A1 | Methods for Treating Pancreatic Cancer Using Combination Therapies | MERRIMACK PHARMACEUTICALS, INC. | 2018-01-11 | — | — | US | claimed |
| WO-2017004518-A1 | SITE-TARGETED NANO-LIPOSOMAL NITROGLYCERIN THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-05 | — | — | WO | claimed |
| WO-2016191556-A1 | LIPOSOMAL NANOCONSTRUCTS AND METHODS OF MAKING AND USING THE SAME | THE GENERAL HOSPITAL CORPORATION (US) | 2016-12-01 | — | — | WO | claimed |
| US-20160287717-A1 | Core and Surface Modification of Mesoporous Silica Nanoparticles to Achieve Cell Specific Targeting In Vivo. | STC UNM (US) | 2016-10-06 | — | — | US | claimed |
| EP-1315506-A4 | PHOSPHOLIPID DERIVATIVES OF VALPROIC ACID AND MIXTURES THEREOF | DPHARM LTD (IL) | 2005-03-30 | — | — | EP | claimed |
| EP-1315506-A2 | PHOSPHOLIPID DERIVATIVES OF VALPROIC ACID AND MIXTURES THEREOF | D-Pharm Ltd (IL) | 2003-06-04 | — | — | EP | claimed |
| WO-2002007669-A2 | PHOSPHOLIPID DERIVATIVES OF VALPROIC ACID AND MIXTURES THEREOF | D-PHARM LTD. (IL) | 2002-01-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041786-A1 | AMINO ALCOHOL IONIZABLE LIPIDS | SLC43A1, METTL16, SLC7A1 | LMNA 692/4885ESR1 3300/4885ADORA3 1514/4885 |
| US-20240108585-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, PNLIP, LIPC | LMNA 1225/4885ESR1 2838/4885ADORA3 2353/4885 |
| US-20180008591-A1 | Methods for Treating Pancreatic Cancer Using Combination Therapies | PNLIP, RNASE1, LPXN | LMNA 2596/4885ESR1 4750/4885ADORA3 1744/4885 |
| US-11666534-B2 | Methods of administering lipid formulations with viral immunogens | STING1, CGAS, PLA2G2A | LMNA 2211/4885ESR1 4470/4885ADORA3 757/4885 |
| US-20240009281-A1 | MRNA THERAPY FOR POMPE DISEASE | GAA, GBA1, GBA2 | LMNA 692/4885ESR1 4122/4885ADORA3 3289/4885 |
| US-20190054021-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | LMNA 1192/4885ESR1 1713/4885ADORA3 1924/4885 |
| US-11638694-B2 | Vaccine for eliciting immune response comprising lipid formulations and RNA encoding multiple immunogens | STING1, CGAS, MYD88 | LMNA 3642/4885ESR1 4170/4885ADORA3 593/4885 |
| US-10369122-B2 | Benzene-1,3,5-tricarboxamide derivatives and uses thereof | POLRMT, POLN, MTREX | LMNA 149/4885ESR1 3576/4885ADORA3 1748/4885 |
| US-20200375913-A1 | COMPOSITIONS COMPRISING LIPID-BASED NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, PNLIP, LIPC | LMNA 1225/4885ESR1 2838/4885ADORA3 2353/4885 |
| US-20230277457-A1 | METHODS OF PREPARING LIPID NANOPARTICLES | PLTP, LIPA, CETP | LMNA 280/4885ESR1 4794/4885ADORA3 3679/4885 |
| US-20230310571-A1 | HUMAN METAPNEUMOVIRUS VACCINES | RNMT, SYNCRIP, METTL16 | LMNA 2275/4885ESR1 4524/4885ADORA3 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.